Abstract：Objective To analyze the clinical effect of levamlodipine besylate combined with valsartan in the treatment of hypertension patients. Methods From October 2019 to October 2021, 100 hypertensive patients were taken as research subjects. They were divided into 50 cases in the reference group （valsartan treatment） and 50 cases in the study group （valsartan combined with levamlodipine benzenesulfonate treatment） based on different treatment plans. The clinical efficacy, blood pressure levels pre- and post-treatment, post-treatment quality of life scores, and the incidence of adverse reactions during the medication period were compared between the two groups. Results After treatment, the blood pressure levels of both groups were reduced, and the study group was better than the reference group, with statistically significant differences in all intergroup comparisons （t＝5.652, 5.320, both P＜0.05）; the total effective rate of treatment in the study group was higher than that of the reference group, with statistically significant differences in intergroup comparisons （χ2＝4.332, P＜0.05）; all the quality of life scores in the study group were higher than those of the reference group, and the differences between the groups were all statistically significant （t＝5.866, 8.167, 5.739, 7.087, all P＜0.05）; the incidence rate of adverse reactions in the study group was slightly higher than that of the reference group, but the differences between the groups were not statistically significant （χ2＝0.177, P＞0.05）. Conclusion The efficacy of single use of valsartan has some limitations, and the combined with levamlodipine besylate can play a synergistic effect for hypertension patients. The efficacy is more significant, and is conducive to the improvement of the patient’s blood pressure level and the quality of life, and the safety of the patients, it is worthy of promotion and application.